Form 4: NextCure Director John G. Houston Acquires 18,700 Stock Options

NextCure, Inc. Director John G. Houston has acquired 18,700 stock options with an exercise price of $0.47, vesting by June 2026.

Summary

• John G. Houston, a Director of NextCure, Inc. (NXTC), was granted 18,700 stock options.
• The stock options have an exercise price of $0.47 per share.
• The grant date for these options was June 20, 2025.
• The options will vest in full on the earlier of June 20, 2026, or the date of the 2026 Annual Meeting of Stockholders.
• Each option represents the right to purchase one share of NextCure Common Stock.
• The expiration date for these stock options is June 19, 2035.
• Following this transaction, Mr. Houston beneficially owns 18,700 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The acquisition of stock options by a director is generally viewed positively as it aligns their interests with shareholder value creation, though it is a routine compensation event.

Positives

• The acquisition of stock options by a director may signal confidence in the company's future performance and stock appreciation, as their compensation becomes more aligned with shareholder value.

Future Outlook

The stock options are structured to vest in full by June 20, 2026, or the date of the 2026 Annual Meeting of Stockholders, aligning the director's incentives with future company performance and potential stock appreciation.

Industry Context

This Form 4 filing reflects a standard equity compensation practice for directors in publicly traded biotechnology companies, aiming to align their interests with shareholder value creation.

Related Party Transactions

• The grant of 18,700 stock options to John G. Houston, a Director of NextCure, Inc., constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aligns their financial interests with the long-term performance of the company, potentially benefiting shareholders through increased focus on stock appreciation.

Next Steps

• The stock options will vest in full on the earlier of June 20, 2026, or the date of the 2026 Annual Meeting of Stockholders.

Key Dates

Keywords

NextCure, NXTC, Stock Option, Insider Transaction, Form 4, Director, Equity Compensation, John G. Houston